La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cyclacel Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cyclacel Pharmaceuticals..

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Azioni, Catena delle Opzioni

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cycclone Inc

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 72.8% to $24.2 during Thursday's pre-market session. The market value of their outstanding shares is at $22.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 27.08% to $8.22. The company's market cap stands at $170.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 25.0% to $0.03. The company's market cap stands at $10.2 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock rose 22.69% to $0.6. The market value of their outstanding shares is at $24.9 million. </li>
<li>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) stock moved upwards by 22.34% to $278.1. The company's market cap stands at $16.3 billion. As per the press release, Q2 earnings came out today. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) shares increased by 16.12% to $5.4. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares declined by 30.4% to $2.7 during Thursday's pre-market session. The company's market cap stands at $544.3 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares declined by 19.21% to $1.43. The market value of their outstanding shares is at $27.2 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 14.9% to $1.6. The market value of their outstanding shares is at $10.0 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 13.94% to $1.05. The company's market cap stands at $6.0 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock decreased by 10.6% to $0.52. The market value of their outstanding shares is at $45.4 million. </li>
<li>Hyperion DeFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPD#NASDAQ">HYPD</a>) stock decreased by 9.88% to $8.4. The market value of their outstanding shares is at $47.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADGM

CLSD

CYCC

CYCCP

HCTI

HYPD

LIMN

PALI

PLRZ

PSTV

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares moved upwards by 48.9% to $460.02 during Monday's after-market session. The market value of their outstanding shares is at $8.9 billion. The company's, Q2 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock increased by 7.65% to $3.78. The company's market cap stands at $125.7 million. </li>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) stock rose 7.54% to $2.28. The market value of their outstanding shares is at $72.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 7.37% to $12.52. The market value of their outstanding shares is at $20.7 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock rose 7.36% to $0.65. The company's market cap stands at $39.1 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares increased by 6.81% to $160.0. The company's market cap stands at $7.8 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 9.8% to $0.02 during Monday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares fell 9.65% to $1.78. The market value of their outstanding shares is at $60.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.51% to $0.12. The company's market cap stands at $1.2 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares declined by 7.07% to $0.27. The market value of their outstanding shares is at $11.7 million. </li>
<li>Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) stock fell 6.6% to $2.55. The company's market cap stands at $24.9 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 6.11% to $0.54. The market value of their outstanding shares is at $25.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRNS

DHAI

GNLX

MEDP

NRXS

ONMD

OVID

TNFA

12 Health Care Stocks Moving In Monday's After-Market Session

News

CORRECTION: Cycle Pharmaceuticals Is Not A Public Listed Company

<h3>Gainers</h3>
<ul>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares rose 104.1% to $11.9 during Monday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares increased by 86.62% to $16.61. The market value of their outstanding shares is at $6.2 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares rose 46.3% to $3.76. The company's market cap stands at $23.8 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares increased by 42.85% to $0.12. The market value of their outstanding shares is at $1.2 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares rose 23.94% to $2.33. The company's market cap stands at $11.3 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares rose 17.08% to $1.85. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 12.7% to $3.72 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) shares decreased by 11.85% to $2.01. The market value of their outstanding shares is at $67.8 million. </li>
<li>Lisata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) shares decreased by 11.07% to $2.25. The company's market cap stands at $21.7 million. </li>
<li>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) stock fell 7.53% to $37.5. The company's market cap stands at $6.1 billion. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares declined by 7.45% to $9.2. The market value of their outstanding shares is at $8.2 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 7.04% to $12.15. The market value of their outstanding shares is at $20.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ATNF

BRKR

GCTK

HSDT

LSTA

RNAZ

SABS

TELO

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) rose sharply in pre-market trading ahead of the S&amp;P 500 debut of the Jack Dorsey-founded <a href="https://www.benzinga.com/quote/XYZ">fintech company</a>.
Block will replace Hess Corp. in the S&amp;P 500 effective prior to the opening of trading on Wednesday, July 23.
Block shares jumped 9.6% to $79.81 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares jumped 82% to $10.61 in pre-market trading.</li>
<li>Dynamix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNX#NASDAQ">DYNX</a>) surged 55.4% to $15.73 in pre-market trading. The Wall Street Journal reported Dynamix plans merger to form The Ether Machine.</li>
<li>TNF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares gained 54% to $0.1347 in pre-market trading after declining around 8% on Friday.</li>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) rose 42.2% to $0.8674 in pre-market trading after jumping 65% on Friday.</li>
<li>LM Funding America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) gained 27.8% to $4.13 in pre-market trading after gaining more than 45% on Friday.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) climbed 27.3% to $0.0598 in pre-market trading after gaining 13% on Thursday.</li>
<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) rose 18.1% to $2.22 in pre-market trading.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) surged 14.1% to $4.30 in pre-market trading after gaining 17% on Friday.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) surged 12.3% to $2.53 in pre-market trading after gaining 36% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) dipped 15.2% to $1.34 in pre-market trading after gaining 52% on Friday.</li>
<li>Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) dipped 13.6% to $1.97 in pre-market trading. Telomir Pharmaceuticals shares jumped 88% on Friday after the company announced data for its gene silencing of STAT1.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 11.3% to $3.78 in pre-market trading after the company updated its revenue guidance for the fiscal year 2025.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares tumbled 10% to $11.77 in pre-market trading after jumping over 58% on Friday.</li>
<li>K-TECH Solutions Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMRK#NASDAQ">KMRK</a>) fell 8.2% to $2.25 in pre-market trading after dipping 45% on Friday.</li>
<li>Majestic Ideal Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) declined 7.9% to $3.04 in pre-market trading after dipping 45% on Friday.</li>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) fell 7.1% to $0.0798 in pre-market trading after declining around 9% on Friday.</li>
<li>Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) fell 7.1% to $0.7061 in pre-market trading after falling 4% on Friday.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) fell 6.4% to $15.79 in pre-market trading. Webull filed for up to 75.16 million share ordinary stock offering by selling shareholder.</li>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares fell 4% to $2.86 in pre-market trading after jumping 18% on Friday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ACET

BULL

DYNX

IXHL

KMRK

LMFA

MJID

OPEN

SLDP

SVRE

WLGS

XPON

Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares rose 35.1% to $0.34 during Friday's after-market session. The company's market cap stands at $11.2 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock increased by 25.71% to $0.11. The market value of their outstanding shares is at $1.3 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock rose 25.33% to $5.64. The company's market cap stands at $9.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 14.75% to $6.69. The market value of their outstanding shares is at $3.3 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock increased by 12.14% to $1.2. The company's market cap stands at $19.2 million. </li>
<li>Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) shares rose 9.54% to $10.9. The company's market cap stands at $656.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 9.7% to $11.81 during Friday's after-market session. The market value of their outstanding shares is at $13.0 million. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares declined by 8.26% to $3.5. The market value of their outstanding shares is at $35.0 million. </li>
<li>Aptorum Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares fell 6.22% to $1.51. The company's market cap stands at $14.0 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock decreased by 5.11% to $1.3. The market value of their outstanding shares is at $22.1 million. </li>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) shares fell 5.0% to $0.9. The company's market cap stands at $15.2 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares fell 4.73% to $0.92. The company's market cap stands at $8.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVX

CLNN

HCWB

LEXX

OSRH

VSEE

YCBD

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) shares rose 90.1% to $2.3 during Friday's regular session. The company's market cap stands at $36.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 63.18% to $13.43. The market value of their outstanding shares is at $13.0 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 40.21% to $1.29. The company's market cap stands at $66.1 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares increased by 27.67% to $15.76. The company's market cap stands at $1.5 billion. </li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) shares rose 24.01% to $5.58. The company's market cap stands at $29.9 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares rose 18.42% to $2.02. The market value of their outstanding shares is at $276.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares fell 35.5% to $14.17 during Friday's regular session. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares fell 25.4% to $0.45. The market value of their outstanding shares is at $46.7 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock fell 21.06% to $6.15. The market value of their outstanding shares is at $24.6 million. </li>
<li>Hyperion DeFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPD#NASDAQ">HYPD</a>) stock fell 20.15% to $12.66. The company's market cap stands at $80.9 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares fell 19.43% to $1.95. The company's market cap stands at $5.5 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 16.67% to $3.6. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MEIP

MESO

NMRA

RDHL

SONN

SRPT

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Friday's Intraday Session

Cyclacel Pharmaceuticals Shares Resume Trade

Cyclacel Pharmaceuticals Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 73.9%

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 43.5%

<h3>Gainers</h3>
<ul>
<li>Aptorum Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock increased by 252.7% to $3.42 during Wednesday's regular session. The company's market cap stands at $6.9 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock increased by 121.17% to $15.25. The market value of their outstanding shares is at $30.1 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 96.18% to $2.0. The company's market cap stands at $41.1 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares rose 27.14% to $0.89. The market value of their outstanding shares is at $52.7 million. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) shares rose 26.46% to $0.54. The market value of their outstanding shares is at $28.5 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares increased by 24.95% to $6.66. The market value of their outstanding shares is at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares decreased by 33.8% to $0.36 during Wednesday's regular session. The market value of their outstanding shares is at $2.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 29.93% to $8.64. The market value of their outstanding shares is at $19.5 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock declined by 15.13% to $2.1. The market value of their outstanding shares is at $59.3 million. </li>
<li>Ardent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) stock declined by 13.44% to $12.05. The company's market cap stands at $1.9 billion. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock declined by 12.21% to $3.98. The market value of their outstanding shares is at $2.3 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 11.83% to $0.67. The company's market cap stands at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDT

CELU

GBIO

NUWE

ONCO

SLXN

SSII

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded mixed this morning, with the Nasdaq falling around 0.1% on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.08% to 44,060.17 while the NASDAQ fell 0.05% to 20,667.98. The S&amp;P 500 also rose, gaining, 0.03% to 6,245.49.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46413798/morgan-stanley-how-to-earn-500-a-month-from-q2-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Health care shares jumped by 1.2% on Wednesday.
In trading on Wednesday, energy stocks dipped by 0.8%.
Top Headline
Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) posted better-than-expected second-quarter financial earnings.
Bank of America reported second-quarter fiscal 2025 net income of $7.1 billion (versus $6.9 billion a year ago) and EPS of $0.89, beating the analyst consensus estimate of $0.87. Revenue, net of interest expense, increased 4% year-over-year (Y/Y) to $26.5 billion, missing the analyst consensus estimate of $26.8 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares shot up 254% to $3.4413 after the company announced it entered into an all-stock merger agreement with DiamiR. DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group.</li>
<li>Shares of Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) got a boost, surging 140% to $16.58 after the company announced it secured a U.S. patent for an extracorporeal blood filtering machine and methods.</li>
<li>Barinthus Biotherapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares were also up, gaining 92% to $1.96.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares dropped 33% to $0.5083 after the company announced the pricing of $5 million public offering.</li>
<li>Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) were down 25% to $9.20.</li>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) was down, falling 22% to $3.5150. Onconetix and Ocuvex Therapeutics announced execution of definitive merger agreement.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $65.81 while gold traded up 0.3% at $3,347.00.
Silver traded down 0.2% to $38.035 on Wednesday, while copper fell 1.6% to $5.49.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 slipped 0.2%, while Spain's IBEX 35 Index rose 0.3%. London's FTSE 100 gained 0.2%, Germany's DAX 40 rose 0.3% and France's CAC 40 fell 0.1% during the session.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.04%, Hong Kong's Hang Seng falling 0.29%, China's Shanghai Composite falling 0.04% and India's BSE Sensex gaining 0.08%.
Economics
<ul class="wp-block-list">
<li>U.S. crude oil inventories declined by 3.859 million barrels in the week ended July 11.</li>
<li>U.S. industrial production increased by 0.3% in June, topping market estimates of a 0.1% rise.</li>
<li>U.S. producer prices came in unchanged in June from May, compared to a revised 0.3% gain in the previous period.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46440451/nvidia-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-wednesday">Nvidia To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

SLNH

US Stocks Mixed; Bank of America Earnings Top Views

Cyclacel Pharmaceuticals Says Not Aware Of Any Material Developments Or Changes To Operating Or Financial Condition That Precipitated Jul. 15 Volume And Price Movements

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 146.7% to $17.01 during Wednesday's pre-market session. The market value of their outstanding shares is at $30.1 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares moved upwards by 19.15% to $1.83. The company's market cap stands at $110.1 million. </li>
<li>Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) shares rose 15.81% to $10.25. The company's market cap stands at $561.7 million. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares increased by 13.28% to $1.62. The market value of their outstanding shares is at $61.3 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) stock increased by 9.4% to $12.85. The market value of their outstanding shares is at $229.0 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares increased by 9.04% to $0.71. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined by 32.9% to $8.27 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.5 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares declined by 27.23% to $2.7. The company's market cap stands at $11.2 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares declined by 22.65% to $0.91. The market value of their outstanding shares is at $19.7 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares fell 15.3% to $1.44. The market value of their outstanding shares is at $50.2 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 13.31% to $2.15. The company's market cap stands at $59.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock fell 12.63% to $1.73. The company's market cap stands at $7.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBIO

CTOR

GANX

KAPA

LIXT

MYNZ

RPTX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Data Storage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) rose sharply in pre-market trading after the company announced plans to sell its subsidiary, CloudFirst, and <a href="https://www.benzinga.com/quote/DTST">initiate a share buyback</a>.
According to Chuck Piluso, CEO of Data Storage Corporation, &#8220;This agreement highlights the long-term value CloudFirst has created and reflects confidence in the future. While the transaction remains subject to shareholder approval, operations at CloudFirst remain unchanged, with no changes to structure or leadership.&#8221;&nbsp;
Data Storage shares jumped 34.9% to $4.52 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) climbed 99% to $0.1450 in pre-market trading following the announcement of a strategic plan by the company's CEO Chris Lai, to prevent delisting from the NASDAQ.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) surged 66.5% to $11.47 in pre-market trading after the company announced it secured a U.S. patent for an extracorporeal blood filtering machine and methods.</li>
<li>GameSquare Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>) jumped 36.4% to $2.06 in pre-market trading after billionaire PayPal and Palantir co-founder Peter Thiel disclosed a stake in the company.</li>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) gained 25.2% to $0.4256 in pre-market trading. Incannex Healthcare appointed Douglas Kirsch to its Advisory Board on June 24.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) jumped 24.1% to $49.50 in pre-market trading.</li>
<li>TNF Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) gained 22.3% to $0.1299 in pre-market trading after adding 4% on Tuesday.</li>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) gained 20.3% to $1.72 in pre-market trading after the company entered a licensing agreement with Debiopharm for Lunresertib.</li>
<li>ABIVAX Société Anonyme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) gained 15.3% to $10.20 in pre-market trading.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares jumped 12.6% to $32.62 in pre-market trading. SharpLink Gaming shares gained 21% on Tuesday after the company provided updates on its ETH holdings and staking protocols.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) declined 40.7% to $0.4532 in pre-market trading after the company announced the pricing of $5 million public offering.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) dipped 34.6% to $8.07 in pre-market trading after jumping over 272% on Tuesday.</li>
<li>PicoCELA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) dipped 28.4% to $0.5802 in pre-market trading after dipping 76% on Tuesday.</li>
<li>Kairos Pharma, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NASDAQ">KAPA</a>) shares tumbled 20.1% to $0.9350 in pre-market trading after jumping over 70% on Tuesday.</li>
<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) fell 17.1% to $1.41 in pre-market trading after announcing a proposed public offering.</li>
<li>Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) fell 14.5% to $2.12 in pre-market trading after gaining over 10% on Tuesday.</li>
<li>Xcel Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) declined 7.4% to $1.50 in pre-market trading. Xcel Brands recently entered into a licensing partnership with K9 Wear Inc. to develop and launch a new pet brand.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) fell 8.3% to $754.34 in pre-market trading after the company warned investors that its growth outlook for 2026 is now under a cloud, citing rising macroeconomic uncertainties and escalating trade tensions.</li>
<li>Smart Digital Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDM#NASDAQ">SDM</a>) fell 5.1% to $13.00 in pre-market trading after dipping over 8% on Tuesday.</li>
<li>Pitanium Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTNM#NASDAQ">PTNM</a>) shares fell 4.8% to $13.30 in pre-market trading after jumping 47% on Tuesday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46415122/top-2-tech-telecom-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Tech &amp; Telecom Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

ASML

BMNR

DTST

GAME

PCLA

PTNM

SBET

Morgan Stanley Capital-Protected Notes Based on Value of S&P 500 Index

XELB

Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock rose 29.1% to $8.9 during Tuesday's after-market session. The market value of their outstanding shares is at $34.1 million. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock increased by 18.18% to $1.69. The market value of their outstanding shares is at $67.3 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares rose 8.84% to $10.58. The market value of their outstanding shares is at $54.2 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 8.44% to $1.67. The market value of their outstanding shares is at $138.8 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares moved upwards by 6.74% to $22.0. The company's market cap stands at $312.0 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock moved upwards by 6.43% to $1.82. The market value of their outstanding shares is at $21.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined by 23.8% to $9.4 during Tuesday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares fell 14.71% to $1.45. The market value of their outstanding shares is at $54.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares fell 9.41% to $1.06. The company's market cap stands at $11.5 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock decreased by 6.44% to $0.29. The market value of their outstanding shares is at $45.8 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares declined by 6.34% to $1.33. The company's market cap stands at $66.1 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 6.06% to $2.33. The company's market cap stands at $53.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

IKNA

PTHL

RBOT

SCNX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 400.0% to $16.55 during Tuesday's regular session. The company's market cap stands at $5.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 99.62% to $5.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 65.66% to $1.14. The company's market cap stands at $11.5 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 34.23% to $0.92. The company's market cap stands at $3.6 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 20.0% to $3.96. The company's market cap stands at $9.2 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock increased by 18.16% to $5.61. The company's market cap stands at $919.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares fell 38.8% to $0.43 during Tuesday's regular session. The company's market cap stands at $27.4 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares decreased by 29.09% to $28.8. The company's market cap stands at $161.8 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares decreased by 24.79% to $13.14. The market value of their outstanding shares is at $351.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 24.22% to $0.7. The market value of their outstanding shares is at $1.9 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock declined by 18.94% to $1.75. The company's market cap stands at $3.1 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) stock declined by 14.23% to $3.77. The company's market cap stands at $189.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INKT

KYTX

RANI

SXTP

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock is trading higher on Tuesday, with a session volume of 21.9 million compared to the average volume of 206.9K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
Notably, there is no news to justify the stock movement.
<h2 class="wp-block-heading">Here&#8217;s what happened with the company recently:</h2>
Last week, Cyclacel entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad, an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, &#8220;Waste-To-Resource&#8221; services and real estate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46269846/cyclacel-pharmaceuticals-announces-amendment-to-exchange-agreement" rel="noreferrer noopener">development and construction</a>.
The company highlighted a publication from independent investigators published online in the journal Gut.
The study&#8217;s authors described in the publication reported that DNAJ-PKAc, a fusion oncoprotein known to drive FLC progression, makes the cancer sensitive to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46269854/cyclacel-pharmaceuticals-highlights-publication-of-preclinical-data-showing-that-plogosertib-is-ac" rel="noreferrer noopener">treatment with plogosertib</a>.
The researchers found that PLK1 is essential for FLC cells, making them highly sensitive to loss of PLK1.
A direct interaction was found between DNAJ-PKAc fusions in the centrosome and PLK1, thus promoting mitotic progression.
Pharmacologic inhibitors of PLK1, such as plogosertib, significantly reduced FLC growth but spared normal liver cells in patient-derived in vitro and in vivo xenograft models and an orthotopic model.
In July, Cyclacel implemented a second <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46218616/cyclacel-pharmaceuticals-announces-stock-split" rel="noreferrer noopener">reverse stock split</a>, 1-for-15, and in May, it announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45251639/cyclacel-pharmaceuticals-announces-stock-split" rel="noreferrer noopener">1-for-16 reverse stock split</a>.
In June, Cyclacel announced a private placement yielding gross proceeds of $3.0 million. The company issued series A, B and C warrants to purchase 3.27 million shares for each warrant at an exercise price of 51 cents per share, 60 cents per share and <a href="https://www.benzinga.com/pressreleases/25/06/g46038528/cyclacel-pharmaceuticals-announces-3-million-private-placement-offering-of-convertible-preferred-s" target="_blank" rel="noreferrer noopener">68 cents per share, respectively</a>.
CYCC Price Action: Cyclacel stock is up 318.43% at $13.85 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers" target="_blank" rel="noreferrer noopener">Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?</a> Photo: Shutterstock</li>
</ul>

Biotech

Health Care

General

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 398.5%

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 348.6%

Earnings

Press Releases

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Financing

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Stock Split

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Comments

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO